Micro Cap Innovation Screener

Screening 224 micro caps ($50M-$500M) for patent activity, cash runway, revenue growth, and management quality. 166 passed, 38 auto-rejected. Data as of 2026-06-20 09:49.

Read the 7-step methodology →

166

Passed Screening

Red Flag Rejected

Score 8+

With Patents

Ticker	Score	Patents	Runway	Rev Growth	Mkt Cap	FCF%	GM%	D/E	Insider %	Tag
NNDM Nano Dimension Ltd.	11/12	15	52mo	+106.4%	$282.4M	-19.8	34	6	5.5%	Computer Hardware
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 3/3 • Mgmt: 2/3 Financials Revenue: $117.8M Cash: $439.8M FCF: $-55.9M ROE: -21.9% • D/E: 6% Profit Margin: -286.7% Quality Low Debt FCF insufficient_data Patents (15) • Electromagnetic band gap element structure and fabrication methods • Systems and methods for additive manufacturing passive resistor-capacitor frequency pass filter (PRC FPF) • System and method for mimicking a neural network without access to the original training dataset or the target model +2 more — view all Full assessment →
NNBR NN, Inc.	11/12	1106	CF+	+12.1%	$147.2M	-0.2	15	152	35.2%	Industrials
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $435.0M Cash: $8.5M FCF: $-0.4M ROE: -21.8% • D/E: 152% Profit Margin: -7.8% Quality FCF insufficient_data Patents (1106) • Heads up display • Adjustable adhesive articles with permissible movement parallel to bonding plane • Film-initiated cure of structural adhesive film +2 more — view all Full assessment →
RNA Atrium Therapeutics, Inc.	11/12	21	52mo	+1148.3%	$216.6M	-	-33	1	7.9%	Biotech
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 3/3 • Mgmt: 2/3 Financials Revenue: $36.7M Cash: $267.8M FCF: N/A ROE: N/A • D/E: 1% Profit Margin: -160.0% Quality Low Debt FCF insufficient_data Patents (21) • Compositions and methods for treating ornithine transcarbamylase deficiency • Molecules and agents for treating hepatitis B virus • Coronavirus vaccine compositions and methods +2 more — view all Full assessment →
KIDS OrthoPediatrics Corp.	11/12	13	147mo	+13.3%	$484.7M	-1.2	73	33	33.5%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $243.3M Cash: $48.8M FCF: $-6.0M ROE: -11.6% • D/E: 33% Profit Margin: -16.3% Quality Low Debt FCF insufficient_data Patents (13) • Segmental tensioning of spinal tethers • Multiple track system for positioning of bone segments • Bone anchors with cord retention features +2 more — view all Full assessment →
PERF Perfect Corp.	11/12	11	CF+	+12.0%	$171.1M	4.5	78	0	66.2%	Application Software
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $71.1M Cash: $161.3M FCF: $7.8M ROE: 3.1% • D/E: 0% Profit Margin: 6.6% Quality FCF+ Low Debt FCF insufficient_data Patents (11) • Systems and methods for segment-based virtual application of facial effects to facial regions displayed in video frames • Systems and methods for contactless estimation of ring size • System and method for personality prediction using multi-tiered analysis +2 more — view all Full assessment →
TYGO Tigo Energy, Inc.	11/12	15	CF+	+33.7%	$211.8M	4.9	44	6	62.1%	Solar Energy
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $109.9M Cash: $11.6M FCF: $10.3M ROE: 15.1% • D/E: 6% Profit Margin: 3.1% Quality FCF+ Low Debt High ROE Wide Moat Buffett FCF insufficient_data Patents (15) • Systems and methods for remote or local shut-off of a photovoltaic system • Systems and methods for remote or local shut-off of a photovoltaic system • Synchronization of signals transmitted over power lines +2 more — view all Full assessment →
SGHT Sight Sciences, Inc.	10/12	17	41mo	+12.5%	$287.3M	-3.0	86	78	35.4%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $79.6M Cash: $85.0M FCF: $-8.6M ROE: -56.6% • D/E: 78% Profit Margin: -46.8% Quality FCF insufficient_data Patents (17) • Controller for dry eye treatment systems • Devices and methods for intraocular tissue manipulation • Ocular delivery systems and methods +2 more — view all Full assessment →
GSIT GSI Technology, Inc.	10/12	29	51mo	+7.4%	$289.9M	-2.6	54	10	17.1%	Semiconductors
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $25.1M Cash: $67.2M FCF: $-7.7M ROE: -24.1% • D/E: 10% Profit Margin: -52.7% Quality Low Debt FCF insufficient_data Patents (29) • In memory matrix multiplication and its usage in neural networks • Reference distance similarity search • Memory device for determining an extreme value +2 more — view all Full assessment →
DERM Journey Medical Corporation	10/12	5	49mo	+21.5%	$171.3M	-1.9	65	83	30.6%	Pharma
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $64.7M Cash: $27.2M FCF: $-3.3M ROE: -36.6% • D/E: 83% Profit Margin: -14.8% Quality FCF insufficient_data Patents (5) • Iron • Handheld steamer • Air detoxifier +2 more — view all Full assessment →
CTKB Cytek Biosciences, Inc.	10/12	11	431mo	+6.5%	$486.9M	1.3	52	8	25.3%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $204.2M Cash: $262.2M FCF: $6.4M ROE: -20.9% • D/E: 8% Profit Margin: -36.2% Quality FCF+ Low Debt FCF insufficient_data Patents (11) • Cell sorter with pivotal scuppers • Smart flow cytometers with self monitoring fluidics • Methods of forming multi-color fluorescence-based flow cytometry panel +2 more — view all Full assessment →
KRMD KORU Medical Systems, Inc.	9/12	2	CF+	+22.1%	$179.1M	0.5	62	20	38.3%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $43.3M Cash: $8.8M FCF: $0.9M ROE: -13.7% • D/E: 20% Profit Margin: -5.3% Quality FCF+ Low Debt FCF insufficient_data Patents (2) • Needle insertion device • Needle insertion device Full assessment →
ALLT Allot Ltd.	9/12	3	CF+	+14.1%	$351.3M	4.7	72	5	36.5%	Enterprise Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $105.3M Cash: $94.2M FCF: $16.5M ROE: 7.2% • D/E: 5% Profit Margin: 5.7% Quality FCF+ Low Debt FCF insufficient_data Patents (3) • Method, system, and device of cellular traffic monitoring • System, device, and method of protecting electronic devices against fraudulent and malicious activities • System, method, and apparatus of securing and managing internet-connected devices and networks Full assessment →
HYPR Hyperfine, Inc.	9/12	43	18mo	+82.6%	$158.8M	-10.2	51	38	5.0%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 2/3 Financials Revenue: $15.3M Cash: $40.8M FCF: $-16.3M ROE: -89.8% • D/E: 38% Profit Margin: -226.9% Quality Low Debt FCF insufficient_data Patents (43) • Self ensembling techniques for generating magnetic resonance images from spatial frequency data • Systems and methods for performing magnetic resonance imaging with reduced operator interaction • Artefact reduction in magnetic resonance imaging +2 more — view all Full assessment →
WEAV Weave Communications, Inc.	9/12	1	CF+	+17.4%	$413.7M	9.6	72	62	18.9%	Health Tech
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $248.7M Cash: $72.7M FCF: $39.8M ROE: -32.9% • D/E: 62% Profit Margin: -10.1% Quality FCF+ FCF insufficient_data Patents (1) • Method and system to improve driver information and vehicle maintenance Full assessment →
AIRG Airgain, Inc.	9/12	18	101mo	-4.2%	$85.9M	0.3	44	16	18.6%	Communication Equipment
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $51.3M Cash: $7.1M FCF: $0.3M ROE: -23.2% • D/E: 16% Profit Margin: -13.2% Quality FCF+ Low Debt FCF insufficient_data Patents (18) • Multi-band MIMO repeater system with carrier aggregation capability • Antenna assembly for a vehicle • Antenna assembly for a vehicle with sleep sense command +2 more — view all Full assessment →
UEIC Universal Electronics Inc.	9/12	135	CF+	-14.4%	$51.8M	37.0	29	24	25.9%	Technology
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $355.0M Cash: $29.8M FCF: $19.2M ROE: -13.6% • D/E: 24% Profit Margin: -5.5% Quality FCF+ Low Debt FCF insufficient_data Patents (135) • System and method for a self adaptive multi-user program guide • Systems and methods for a customized media access user experience with privacy settings • Controlling device configurable to enable selection of one or more services +2 more — view all Full assessment →
YEXT Yext, Inc.	9/12	24	CF+	-1.4%	$380.9M	7.7	75	918	32.4%	Enterprise Software
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $445.0M Cash: $91.9M FCF: $29.2M ROE: 47.7% • D/E: 918% Profit Margin: 8.9% Quality FCF+ High ROE Wide Moat FCF insufficient_data Patents (24) • Electronic device display or portion thereof with a graphical user interface • Online review generation using a redirection container • Online merchant review system and method utilizing dynamic URL redirection for distributing review requests +2 more — view all Full assessment →
EGHT 8x8 Inc	9/12	112	CF+	+4.6%	$259.8M	26.1	65	253	4.6%	Application Software
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $735.8M Cash: $93.3M FCF: $67.8M ROE: 1.2% • D/E: 253% Profit Margin: 0.2% Quality FCF+ FCF insufficient_data Patents (112) • Server-based service configuration system and approach • Management of VoIP device contact lists in a data communications services system • Analysis of customer interaction metrics from digital voice data in a data-communication server system +2 more — view all Full assessment →
XNET Xunlei Limited	9/12	0	CF+	+53.9%	$315.7M	-	48	6	55.1%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $494.8M Cash: $303.6M FCF: N/A ROE: 113.1% • D/E: 6% Profit Margin: 176.7% Quality Low Debt High ROE Wide Moat FCF insufficient_data Full assessment →
AEYE AudioEye, Inc.	9/12	5	CF+	+8.4%	$78.8M	9.0	78	533	34.2%	Application Software
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $41.1M Cash: $8.6M FCF: $7.1M ROE: -66.9% • D/E: 533% Profit Margin: -9.0% Quality FCF+ FCF insufficient_data Patents (5) • Modular systems and methods for selectively enabling cloud-based assistive technologies • Modular systems and methods for selectively enabling cloud-based assistive technologies • Modular systems and methods for selectively enabling cloud-based assistive technologies +2 more — view all Full assessment →
GEVO Gevo, Inc.	9/12	6	90mo	+47.5%	$374.9M	-2.8	46	37	7.4%	Basic Materials
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $174.4M Cash: $78.9M FCF: $-10.5M ROE: -6.9% • D/E: 37% Profit Margin: -19.4% Quality Low Debt FCF insufficient_data Patents (6) • Selective formation of jet and diesel fuels from bio-based C3-C8 olefins via oligomerization with tungstated catalysts • Simultaneous dehydration, dimerization, and metathesis of C2-C5 alcohols • Upgrading of fusel oils over doped alumina +2 more — view all Full assessment →
ALDX Aldeyra Therapeutics, Inc.	9/12	15	30mo	-	$118.2M	-16.6	-	37	12.7%	Biotech
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $65.0M FCF: $-19.6M ROE: -51.8% • D/E: 37% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (15) • Ophthalmic formulations of methotrexate • Process for preparation of aldehyde scavenger and intermediates • Polymorphic compounds and uses thereof +2 more — view all Full assessment →
ELMD Electromed, Inc.	9/12	1	CF+	+18.4%	$320.3M	2.6	78	0	21.8%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $71.8M Cash: $17.0M FCF: $8.3M ROE: 21.7% • D/E: 0% Profit Margin: 14.1% Quality FCF+ Low Debt High ROE Wide Moat Buffett FCF insufficient_data Patents (1) • Body pulsating apparatus and method Full assessment →
APYX Apyx Medical Corporation	9/12	5	48mo	+32.5%	$172.1M	-4.5	63	302	28.1%	Medical Devices
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $55.9M Cash: $31.1M FCF: $-7.7M ROE: -76.5% • D/E: 302% Profit Margin: -16.4% Quality FCF insufficient_data Patents (5) • Iron • Handheld steamer • Air detoxifier +2 more — view all Full assessment →
CGTX Cognition Therapeutics, Inc.	9/12	29	CF+	-	$129.8M	-	-	2	8.5%	Biotech
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.0M Cash: $36.8M FCF: N/A ROE: N/A • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (29) • Machine-learning based analysis, prediction, and response based on electromagnetic waveforms • Machine-learning based analysis and response based on electromagnetic waveforms and sensor data • Execution of a genetic algorithm having variable epoch size with selective execution of a training algorithm +2 more — view all Full assessment →
FATN FatPipe, Inc.	9/12	0	80mo	+90.4%	$74.2M	-0.5	91	23	43.7%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $19.2M Cash: $5.2M FCF: $-0.3M ROE: 24.2% • D/E: 23% Profit Margin: 25.9% Quality Low Debt High ROE Wide Moat FCF insufficient_data Full assessment →
CAN Canaan Inc.	9/12	14	CF+	-24.3%	$245.0M	-	4	15	23.3%	Computer Hardware
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $509.7M Cash: $43.5M FCF: N/A ROE: -67.9% • D/E: 15% Profit Margin: -41.7% Quality Low Debt FCF insufficient_data Patents (14) • Cooling container for computing devices • Modular computing apparatus with integrated power and signal routing • Waste heat utilization system of immersed liquid cooling heat dissipation device +2 more — view all Full assessment →
GRVY GRAVITY Co., Ltd.	9/12	2	CF+	+18.2%	$455.3M	-	32	1	59.3%	Communication Services
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $569987.6M Cash: $616509.0M FCF: N/A ROE: 11.8% • D/E: 1% Profit Margin: 13.1% Quality Low Debt FCF insufficient_data Patents (2) • Track for rolling vehicle and methods of fabricating and assembling the track • Track for rolling vehicle and methods of fabricating and assembling the track Full assessment →
OVID Ovid Therapeutics Inc.	9/12	1197	44mo	-	$423.7M	-4.9	100	7	18.3%	Biotech
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $7.1M Cash: $155.5M FCF: $-20.8M ROE: -18.8% • D/E: 7% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (1197) • Systems and methods for detecting strokes • Systems and methods for performing a tissue seal • Electromechanical surgical apparatus including wire routing clock spring +2 more — view all Full assessment →
LAB Standard BioTools Inc.	9/12	10	60mo	+4.6%	$324.8M	-4.1	53	5	46.3%	Medical Devices
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $86.3M Cash: $455.2M FCF: $-13.4M ROE: -9.9% • D/E: 5% Profit Margin: 90.7% Quality Low Debt FCF insufficient_data Patents (10) • High resolution imaging apparatus and method • Reagents and methods for elemental mass spectrometry of biological samples • Inductively coupled plasma based atomic analysis systems and methods +2 more — view all Full assessment →
SHIP Seanergy Maritime Holdings Corp	9/12	0	CF+	+77.0%	$317.0M	-	63	110	33.6%	Industrials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $176.7M Cash: $68.8M FCF: N/A ROE: 13.9% • D/E: 110% Profit Margin: 21.3% Quality FCF insufficient_data Full assessment →
MASS 908 Devices Inc.	8/12	0	180mo	+13.6%	$334.7M	4.1	52	3	36.2%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $57.8M Cash: $111.7M FCF: $13.7M ROE: -24.1% • D/E: 3% Profit Margin: -62.4% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
PROF Profound Medical Corp.	8/12	8	16mo	+103.6%	$249.6M	-9.1	71	13	4.1%	Medical Devices
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 2/3 Financials Revenue: $18.8M Cash: $50.3M FCF: $-22.8M ROE: -70.6% • D/E: 13% Profit Margin: -206.8% Quality Low Debt FCF insufficient_data Patents (8) • Multi-channel real-time phase modulation for EMI reduction in an ultrasound device • System and method for open-loop ultrasound therapy to the prostate including restricting the therapy delivered to a predetermined angular range • Ultrasonic therapy applicator and method of determining position of ultrasound transducers +2 more — view all Full assessment →
PSFE Paysafe Limited	8/12	0	CF+	+10.4%	$350.4M	54.8	56	411	54.0%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $1743.1M Cash: $257.2M FCF: $192.1M ROE: -27.0% • D/E: 411% Profit Margin: -11.4% Quality FCF+ FCF insufficient_data Full assessment →
PACB Pacific Biosciences of Californ	8/12	59	30mo	+0.1%	$434.8M	-11.1	38	29856	2.3%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $160.0M Cash: $276.0M FCF: $-48.2M ROE: -273.6% • D/E: 29856% Profit Margin: -80.3% Quality FCF insufficient_data Patents (59) • Methods and compositions for sequencing double stranded nucleic acids • Protected dye-labeled reagents • High speed scanning system with acceleration tracking +2 more — view all Full assessment →
RELL Richardson Electronics, Ltd.	8/12	7	271mo	+3.1%	$270.8M	-3.0	31	1	3.6%	Electronic Components
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $214.3M Cash: $29.5M FCF: $-8.0M ROE: 2.4% • D/E: 1% Profit Margin: 1.8% Quality Low Debt FCF insufficient_data Patents (7) • Hybrid capacitor energy storage • Resistor • Ultracapacitor generator start module +2 more — view all Full assessment →
CXDO Crexendo, Inc.	8/12	0	CF+	+29.0%	$228.9M	3.9	62	1	35.7%	Telecommunications
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $72.8M Cash: $7.2M FCF: $8.9M ROE: 7.0% • D/E: 1% Profit Margin: 6.1% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
SMWB Similarweb Ltd.	8/12	0	CF+	+10.1%	$437.1M	5.8	80	189	53.0%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $289.4M Cash: $65.3M FCF: $25.1M ROE: -134.1% • D/E: 189% Profit Margin: -10.4% Quality FCF+ FCF insufficient_data Full assessment →
RMNI Rimini Street, Inc.	8/12	1	CF+	+1.2%	$385.0M	8.6	60	-	56.6%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $422.8M Cash: $133.8M FCF: $33.3M ROE: N/A • D/E: N/A Profit Margin: 8.3% Quality FCF+ FCF insufficient_data Patents (1) • Method and system for proactive client relationship analysis Full assessment →
BKTI BK Technologies Corporation	8/12	0	CF+	+11.8%	$311.1M	4.7	50	3	23.7%	Communication Equipment
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $88.4M Cash: $29.0M FCF: $14.5M ROE: 35.4% • D/E: 3% Profit Margin: 16.0% Quality FCF+ Low Debt High ROE Wide Moat Buffett FCF insufficient_data Full assessment →
VITL Vital Farms, Inc.	8/12	0	CF+	+15.4%	$446.1M	-12.1	35	16	19.6%	Consumer Defensive
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $784.4M Cash: $51.4M FCF: $-53.9M ROE: 15.4% • D/E: 16% Profit Margin: 6.1% Quality Low Debt High ROE FCF insufficient_data Full assessment →
FHTX Foghorn Therapeutics Inc.	8/12	13	25mo	-45.1%	$243.7M	-15.2	-191	-	53.3%	Biotech
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $28.2M Cash: $183.6M FCF: $-36.9M ROE: N/A • D/E: N/A Profit Margin: -266.9% Quality FCF insufficient_data Patents (13) • Compounds and uses thereof • Compounds and uses thereof • BRD9 degraders and uses thereof +2 more — view all Full assessment →
SMRT SmartRent, Inc.	8/12	4	85mo	-6.4%	$217.9M	-3.2	34	2	11.3%	Application Software
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $149.7M Cash: $98.8M FCF: $-7.1M ROE: -10.3% • D/E: 2% Profit Margin: -16.6% Quality Low Debt FCF insufficient_data Patents (4) • Thermostat • Thermostat • Thermostat +1 more — view all Full assessment →
ZVIA Zevia PBC	8/12	0	CF+	+21.2%	$109.8M	3.0	48	1	30.5%	Consumer Defensive
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $169.3M Cash: $26.6M FCF: $3.3M ROE: -20.0% • D/E: 1% Profit Margin: -4.1% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
CURV Torrid Holdings Inc.	8/12	5	CF+	-7.6%	$192.1M	25.6	34	-	75.8%	Consumer Cyclical
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $979.9M Cash: $22.8M FCF: $49.2M ROE: N/A • D/E: N/A Profit Margin: -1.3% Quality FCF+ FCF insufficient_data Patents (5) • Wire-free push-up brassiere with hinge for improved support and flexibility • Power mesh panels for tummy-covering garments • Wire-free push-up brassiere with hinge for improved support and flexibility +2 more — view all Full assessment →
NEXN Nexxen International Ltd.	8/12	0	CF+	+10.9%	$479.2M	8.4	84	6	23.3%	Communication Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $373.3M Cash: $94.6M FCF: $40.1M ROE: 3.7% • D/E: 6% Profit Margin: 4.8% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
RNGR Ranger Energy Services, Inc.	8/12	0	CF+	+17.7%	$363.1M	-3.7	17	21	21.4%	Energy Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $570.8M Cash: $6.9M FCF: $-13.3M ROE: 5.1% • D/E: 21% Profit Margin: 2.6% Quality Low Debt FCF insufficient_data Full assessment →
TBRG TruBridge, Inc.	8/12	4	CF+	-1.1%	$391.3M	9.5	53	94	43.2%	Health Tech
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $345.9M Cash: $35.4M FCF: $37.2M ROE: 2.5% • D/E: 94% Profit Margin: 1.3% Quality FCF+ FCF insufficient_data Patents (4) • Process for preparing a patient's jaw for a full arch teeth replacement • Arch preparation system and method for receiving a full arch dental restoration device • Dental restoration system and method +1 more — view all Full assessment →
AIRS AirSculpt Technologies, Inc.	7/12	0	CF+	-	$348.5M	3.7	66	71	78.8%	Healthcare
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $151.8M Cash: $16.7M FCF: $13.0M ROE: -12.6% • D/E: 71% Profit Margin: -7.4% Quality FCF+ FCF insufficient_data Full assessment →
QUIK QuickLogic Corporation	7/12	0	CF+	+16.8%	$388.2M	-	21	14	9.1%	Semiconductors
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $14.5M Cash: $6.0M FCF: N/A ROE: -49.2% • D/E: 14% Profit Margin: -102.3% Quality Low Debt FCF insufficient_data Full assessment →
MVIS Microvision, Inc.	7/12	21	9mo	+58.7%	$125.5M	-24.6	-	135	5.3%	Scientific Instruments
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $1.6M Cash: $46.1M FCF: $-30.9M ROE: -197.3% • D/E: 135% Profit Margin: N/A Quality FCF insufficient_data Patents (21) • LIDAR system with spatial beam combining • Method and device for optically measuring distances • Method and device for optical distance measurement +2 more — view all Red Flags SBC_HIGH (1958% of revenue) Full assessment →
EGAN eGain Corporation	7/12	0	CF+	+7.1%	$206.2M	4.8	74	3	45.2%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $92.2M Cash: $80.5M FCF: $9.8M ROE: 53.7% • D/E: 3% Profit Margin: 41.7% Quality FCF+ Low Debt High ROE Wide Moat Buffett FCF insufficient_data Full assessment →
POWW Outdoor Holding Company	7/12	0	CF+	+53.2%	$251.0M	11.5	95	5	25.5%	Defense & Aerospace
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $46.0M Cash: $69.9M FCF: $28.8M ROE: -10.9% • D/E: 5% Profit Margin: -174.6% Quality FCF+ Low Debt FCF insufficient_data Red Flags SBC_HIGH (68% of revenue) Full assessment →
AVNW Aviat Networks, Inc.	7/12	2	CF+	-11.2%	$259.3M	-3.1	32	39	10.2%	Communication Equipment
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $434.1M Cash: $78.1M FCF: $-8.1M ROE: 3.4% • D/E: 39% Profit Margin: 2.1% Quality Low Debt FCF insufficient_data Patents (2) • Resilient data communications with physical layer link aggregation, extended failure detection and load balancing • Resilient data communications with physical layer link aggregation, extended failure detection and load balancing Full assessment →
SSTI SoundThinking, Inc.	7/12	1	CF+	-14.7%	$101.6M	11.8	52	9	45.7%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $100.0M Cash: $14.4M FCF: $12.0M ROE: -21.1% • D/E: 9% Profit Margin: -14.9% Quality FCF+ Low Debt FCF insufficient_data Patents (1) • Systems and methods for weapon and destructive device detection based on electromagnetic field profile Full assessment →
CODA Coda Octopus Group, Inc.	7/12	3	CF+	-1.6%	$112.8M	3.9	67	1	49.1%	Defense & Aerospace
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $28.0M Cash: $30.6M FCF: $4.4M ROE: 8.4% • D/E: 1% Profit Margin: 17.7% Quality FCF+ Low Debt FCF insufficient_data Patents (3) • Technologies for dynamic, real-time, four-dimensional volumetric multi-object underwater scene segmentation • Method of stabilizing sonar images • Combined method of location of sonar detection device Full assessment →
ARBE Arbe Robotics Ltd.	7/12	6	16mo	+1052.5%	$100.8M	-37.0	-44	53	21.1%	Scientific Instruments
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $1.4M Cash: $53.3M FCF: $-37.3M ROE: -73.6% • D/E: 53% Profit Margin: N/A Quality FCF insufficient_data Patents (6) • Method for separating targets and clutter from noise, in radar signals • Apparatus and method of two-stage signal processing in a radar system • Apparatus and method of eliminating settling time delays in a radar system +2 more — view all Red Flags SBC_HIGH (103% of revenue) Full assessment →
OPAL OPAL Fuels Inc.	7/12	2	CF+	-14.1%	$325.0M	-26.2	26	87	44.0%	Utilities
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $336.9M Cash: $135.8M FCF: $-85.2M ROE: 6.1% • D/E: 87% Profit Margin: 5.7% Quality FCF insufficient_data Patents (2) • Defuel priority panel • Modular and portable compressed natural gas fueling station Full assessment →
BLZE Backblaze, Inc.	7/12	0	CF+	+11.7%	$491.5M	4.3	62	74	4.6%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $149.9M Cash: $45.5M FCF: $21.3M ROE: -27.6% • D/E: 74% Profit Margin: -15.0% Quality FCF+ FCF insufficient_data Full assessment →
GETY Getty Images Holdings, Inc.	7/12	0	CF+	+1.1%	$253.5M	-188.8	73	338	52.9%	Communication Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $983.8M Cash: $96.6M FCF: $-478.7M ROE: -17.6% • D/E: 338% Profit Margin: -10.9% Quality FCF insufficient_data Full assessment →
RBBN Ribbon Communications Inc.	7/12	1	CF+	-10.3%	$450.9M	10.6	52	96	48.8%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $825.9M Cash: $67.6M FCF: $47.8M ROE: 7.8% • D/E: 96% Profit Margin: 3.8% Quality FCF+ FCF insufficient_data Patents (1) • Method and system to improve driver information and vehicle maintenance Full assessment →
ALIT Alight, Inc.	7/12	14	CF+	-2.6%	$311.5M	45.0	38	206	12.0%	Application Software
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $2248.0M Cash: $183.0M FCF: $140.1M ROE: -117.1% • D/E: 206% Profit Margin: -137.5% Quality FCF+ FCF insufficient_data Patents (14) • Obtaining high-resolution oculometric parameters • Display screen or portion thereof with animated graphical user interface • Display screen or portion thereof with animated graphical user interface +2 more — view all Red Flags SBC_HIGH (153% of revenue) Full assessment →
DOMO Domo, Inc.	7/12	2	CF+	-0.9%	$109.3M	37.2	75	-	15.8%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $318.1M Cash: $39.1M FCF: $40.6M ROE: N/A • D/E: N/A Profit Margin: -17.4% Quality FCF+ FCF insufficient_data Patents (2) • Jumper control circuit and jumper device • Device for adjusting polarities of vehicle clamps and starting system Full assessment →
SIGA SIGA Technologies Inc.	7/12	3	CF+	-11.3%	$309.8M	19.2	44	0	42.8%	Pharma
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $93.8M Cash: $145.6M FCF: $59.4M ROE: 11.0% • D/E: 0% Profit Margin: 21.6% Quality FCF+ Low Debt FCF insufficient_data Patents (3) • Polymorphic forms of ST-246 and methods of preparation • ST-246 (tecovirimat monohydrate) suspension formulations • Polymorphic forms of ST-246 and methods of preparation Full assessment →
GDYN Grid Dynamics Holdings, Inc.	7/12	0	CF+	+3.7%	$473.3M	5.7	34	3	29.2%	IT Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $415.5M Cash: $327.5M FCF: $26.8M ROE: 1.0% • D/E: 3% Profit Margin: 1.3% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
MBOT Microbot Medical Inc.	7/12	2	57mo	-	$124.9M	-9.3	2	1	0.0%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.1M Cash: $72.5M FCF: $-11.6M ROE: -27.6% • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (2) • Modular robotic system for driving movement of surgical tools • Device for automatically inserting and manipulating a medical tool into and within a bodily lumen Full assessment →
AVXL Anavex Life Sciences Corp.	7/12	11	46mo	-	$253.0M	-8.6	-	-	3.1%	Biotech
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $131.7M FCF: $-21.8M ROE: -33.6% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (11) • A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy • Neurodevelopmental disorder therapy • Enantiomers of A2-73, analogues, and sigma agonist activity +2 more — view all Red Flags HYPE_PRICING ($0.0M rev, $253M mcap) Full assessment →
AUTL Autolus Therapeutics plc	7/12	0	CF+	-	$401.9M	-	-	-	87.3%	Biotech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $1.1M Cash: $217.4M FCF: N/A ROE: -29.6% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Full assessment →
ORMP Oramed Pharmaceuticals Inc.	7/12	0	92mo	-	$158.8M	0.2	-	0	30.2%	Biotech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $65.8M FCF: $0.3M ROE: 58.2% • D/E: 0% Profit Margin: N/A Quality FCF+ Low Debt High ROE FCF insufficient_data Full assessment →
FULC Fulcrum Therapeutics, Inc.	7/12	4	63mo	-	$246.5M	-15.3	-	2	28.0%	Biotech
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $333.3M FCF: $-37.7M ROE: -27.1% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (4) • Processes for producing high biogenic concentration fischer-tropsch liquids derived from municipal solid wastes (MSW) feedstocks • Processes for producing high biogenic concentration Fischer-Tropsch liquids derived from municipal solid wastes (MSW) feedstocks • Feedstock processing systems and methods for producing Fischer-Tropsch liquids and transportation fuels +1 more — view all Red Flags HYPE_PRICING ($0.0M rev, $247M mcap) Full assessment →
MYPS PLAYSTUDIOS, Inc.	7/12	2	CF+	-6.9%	$68.9M	40.7	77	3	18.5%	Communication Services
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $230.8M Cash: $103.7M FCF: $28.1M ROE: -15.7% • D/E: 3% Profit Margin: -15.8% Quality FCF+ Low Debt FCF insufficient_data Patents (2) • Method, system, and apparatus for enabling players to earn tangible rewards on a social game • Cash slot machine augmented with secondary currency Full assessment →
PMVP PMV Pharmaceuticals, Inc.	7/12	8	15mo	-	$60.3M	-78.1	-	0	19.1%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $93.5M FCF: $-47.1M ROE: -63.2% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (8) • Methods and compounds for restoring mutant p53 function • Deuterated compounds for restoring mutant p53 function • Methods and compounds for restoring mutant p53 function +2 more — view all Full assessment →
PLBY Playboy, Inc.	7/12	0	864mo	+4.7%	$170.4M	1.5	71	522	48.4%	Consumer Cyclical
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $122.3M Cash: $30.2M FCF: $2.6M ROE: -37.2% • D/E: 522% Profit Margin: -6.2% Quality FCF+ FCF insufficient_data Full assessment →
CURI CuriosityStream Inc.	7/12	0	CF+	+0.5%	$150.0M	22.0	57	10	31.3%	Communication Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $71.7M Cash: $20.4M FCF: $33.0M ROE: -17.1% • D/E: 10% Profit Margin: -11.3% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
CNTX Context Therapeutics Inc.	7/12	4	20mo	-	$58.1M	-41.0	-	0	53.4%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $54.5M FCF: $-23.8M ROE: -56.2% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (4) • Method and system for customizing a mobile application using a web-based interface • Flexible online form display • Flexible online form display +1 more — view all Full assessment →
XBIT XBiotech Inc.	7/12	3	33mo	-	$70.4M	-43.5	-	-	25.1%	Biotech
Score Breakdown Patents: 1/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $115.5M FCF: $-30.6M ROE: -25.9% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (3) • Arthritis treatment • Compositions and methods for treating and preventing Staphylococcus aureus infections • Treatment for neoplastic diseases Full assessment →
BRLT Brilliant Earth Group, Inc.	7/12	2	361mo	+6.0%	$106.3M	-1.7	56	54	8.3%	Consumer Cyclical
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $443.1M Cash: $58.6M FCF: $-1.8M ROE: -13.3% • D/E: 54% Profit Margin: -1.1% Quality FCF insufficient_data Patents (2) • Ring • Bracelet Full assessment →
NRDY Nerdy Inc.	7/12	1	38mo	+2.4%	$163.2M	-1.0	64	74	49.5%	Application Software
Score Breakdown Patents: 1/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $180.1M Cash: $44.7M FCF: $-1.7M ROE: -124.5% • D/E: 74% Profit Margin: -18.6% Quality FCF insufficient_data Patents (1) • Non-contact media control system and method Full assessment →
BGSF BGSF, Inc.	7/12	0	252mo	-	$57.9M	28.5	36	2	12.9%	Industrials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $93.3M Cash: $18.9M FCF: $16.5M ROE: -16.4% • D/E: 2% Profit Margin: -12.0% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
CMTL Comtech Telecommunications Corp	7/12	1	CF+	-16.4%	$71.9M	63.5	33	96	15.3%	Communication Equipment
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $454.2M Cash: $28.5M FCF: $45.6M ROE: -9.1% • D/E: 96% Profit Margin: -5.5% Quality FCF+ FCF insufficient_data Patents (1) • Method and system to improve driver information and vehicle maintenance Full assessment →
ASUR Asure Software Inc	7/12	0	CF+	+22.7%	$237.2M	2.2	68	38	9.4%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $148.4M Cash: $19.2M FCF: $5.2M ROE: -5.1% • D/E: 38% Profit Margin: -6.8% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
VYGR Voyager Therapeutics, Inc.	7/12	92	13mo	-59.9%	$224.8M	-36.0	-244	20	26.8%	Biotech
Score Breakdown Patents: 3/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $36.5M Cash: $141.5M FCF: $-80.8M ROE: -52.3% • D/E: 20% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (92) • Micro shutter array for LIDAR signal filtering • Hybrid driving for large aperture tilting mirrors • Micromachined mirror assembly having micro mirror array and hybrid driving method thereof +2 more — view all Full assessment →
UPB Upstream Bio, Inc.	7/12	3	25mo	+82.7%	$340.1M	-26.6	100	0	35.7%	Biotech
Score Breakdown Patents: 1/3 • Runway: 2/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $3.3M Cash: $294.6M FCF: $-90.3M ROE: -41.8% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (3) • Pharmaceutical composition comprising anti-human TSLP receptor antibody • Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same • Pharmaceutical composition comprising anti-human TSLP receptor antibody Red Flags SBC_HIGH (506% of revenue) Full assessment →
SMC Summit Midstream Corporation	7/12	0	CF+	+4.9%	$398.1M	-0.7	46	138	83.9%	Energy
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $569.5M Cash: $43.4M FCF: $-2.7M ROE: -3.5% • D/E: 138% Profit Margin: -4.0% Quality FCF insufficient_data Full assessment →
GNE Genie Energy Ltd.	7/12	0	CF+	+4.0%	$369.1M	7.8	23	3	18.5%	Utilities
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $507.5M Cash: $200.1M FCF: $28.8M ROE: 9.3% • D/E: 3% Profit Margin: 3.2% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
XRX Xerox Holdings Corporation	7/12	0	CF+	+26.7%	$395.0M	137.3	29	840	8.9%	Industrials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $7411.0M Cash: $585.0M FCF: $542.2M ROE: -115.4% • D/E: 840% Profit Margin: -14.1% Quality FCF+ FCF insufficient_data Full assessment →
IONR ioneer Ltd	7/12	895	49mo	-	$309.6M	-	100	0	23.7%	Basic Materials
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 0/3 Financials Revenue: $0.7M Cash: $25.1M FCF: N/A ROE: N/A • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (895) • Maize hybrid X18V372 • Maize inbred 1PHVF50 • Maize inbred 1PHNQ08 +2 more — view all Red Flags SBC_HIGH (305% of revenue) HYPE_PRICING ($0.7M rev, $310M mcap) Full assessment →
EDIT Editas Medicine, Inc.	6/12	23	11mo	-39.2%	$412.8M	-17.9	-109	392	48.3%	Biotech
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $38.7M Cash: $123.6M FCF: $-73.8M ROE: -326.1% • D/E: 392% Profit Margin: -281.6% Quality FCF insufficient_data Patents (23) • Systems and methods for the treatment of hemoglobinopathies • Assessing nuclease cleavage • CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10) +2 more — view all Full assessment →
RXST RxSight, Inc.	6/12	2	149mo	-18.5%	$195.8M	-0.5	77	4	5.4%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $127.5M Cash: $217.9M FCF: $-1.0M ROE: -17.1% • D/E: 4% Profit Margin: -36.6% Quality Low Debt FCF insufficient_data Patents (2) • Light adjustable intraocular lens with a modulable absorption front protection layer • Light adjustable intraocular lens with a modulable absorption front protection layer Full assessment →
SPWR SunPower Inc.	6/12	21	3mo	-7.2%	$113.7M	24.1	50	-	24.4%	Solar Energy
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $294.4M Cash: $9.5M FCF: $27.4M ROE: N/A • D/E: N/A Profit Margin: -15.3% Quality FCF+ FCF insufficient_data Patents (21) • Water sealing surface attachment • Systems and method for determining solar panel placement and energy output • Methods of recycling silicon swarf into electronic grade polysilicon or metallurgical-grade silicon +2 more — view all Full assessment →
PERI Perion Network Ltd	6/12	0	CF+	+1.2%	$351.5M	18.1	34	3	2.3%	Communication Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $441.0M Cash: $293.0M FCF: $63.6M ROE: -1.4% • D/E: 3% Profit Margin: -2.2% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
CRNC Cerence Inc.	6/12	1	CF+	-17.7%	$486.7M	12.6	78	118	3.1%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $302.1M Cash: $108.3M FCF: $61.5M ROE: -12.8% • D/E: 118% Profit Margin: -6.5% Quality FCF+ FCF insufficient_data Patents (1) • Voice assistant error detection system Full assessment →
WRAP Wrap Technologies, Inc.	6/12	13	10mo	+45.2%	$69.1M	-22.4	56	3	27.4%	Scientific Instruments
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 2/3 • Mgmt: 1/3 Financials Revenue: $5.0M Cash: $7.3M FCF: $-15.5M ROE: -176.3% • D/E: 3% Profit Margin: -298.6% Quality Low Debt FCF insufficient_data Patents (13) • Projectile cassette • Systems and methods for generating optical beam arrays • Projectile anchor +2 more — view all Red Flags SBC_HIGH (150% of revenue) Full assessment →
GANX Gain Therapeutics, Inc.	6/12	18	10mo	-	$80.2M	-13.9	-	5	2.4%	Biotech
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.0M Cash: $16.5M FCF: $-11.1M ROE: -214.7% • D/E: 5% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (18) • Multi-band MIMO repeater system with carrier aggregation capability • Antenna assembly for a vehicle • Antenna assembly for a vehicle with sleep sense command +2 more — view all Full assessment →
PLRX Pliant Therapeutics, Inc.	6/12	7	21mo	-	$71.8M	-86.0	-	17	2.7%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.0M Cash: $170.9M FCF: $-61.8M ROE: -53.6% • D/E: 17% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (7) • Amino acid compounds with unbranched linkers and methods of use • Dosage forms and regimens for amino acid compounds • Substituted amino acids as integrin inhibitors +2 more — view all Full assessment →
IMMP Immutep Limited	6/12	1	19mo	+91.5%	$55.1M	-64.7	-	1	2.9%	Biotech
Score Breakdown Patents: 1/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $7.9M Cash: $99.1M FCF: $-35.7M ROE: -61.8% • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (1) • Device for cutting, separation, and discharge of syringe Red Flags SBC_HIGH (275% of revenue) Full assessment →
GOSS Gossamer Bio, Inc.	6/12	0	7mo	+71.5%	$82.1M	-118.4	100	-	94.4%	Biotech
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $55.5M Cash: $99.2M FCF: $-97.3M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Full assessment →
SEER Seer, Inc.	6/12	13	41mo	-33.6%	$95.7M	-33.1	49	10	27.1%	Biotech
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $15.2M Cash: $166.7M FCF: $-31.7M ROE: -25.5% • D/E: 10% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (13) • Device for combining light beams which interact with adjacently arranged pixels of a light modulator • Display device, in particular a head-mounted display, based on temporal and spatial multiplexing of hologram tiles • Spatial light modulator device for the modulation of a wave field with complex information +2 more — view all Red Flags SBC_HIGH (145% of revenue) Full assessment →
IPHA Innate Pharma S.A.	6/12	16	8mo	-46.7%	$170.0M	-20.1	-	-	29.8%	Biotech
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $9.0M Cash: $34.3M FCF: $-34.1M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (16) • Variable regions for NKp46 binding proteins • Treatment of peripheral T cell lymphoma • NKp46 binding agents +2 more — view all Full assessment →
ENLV Enlivex Ltd.	6/12	5	7mo	-	$149.9M	-1159.1	-	-	76.1%	Biotech
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $5.8M FCF: $-1737.1M ROE: 126.2% • D/E: N/A Profit Margin: N/A Quality Low Debt High ROE FCF insufficient_data Patents (5) • Combination immune therapy and cytokine control therapy for cancer treatment • Early apoptotic cells for use treating sepsis • Combination immune therapy and cytokine control therapy for cancer treatment +2 more — view all Full assessment →
TMCI Treace Medical Concepts, Inc.	6/12	0	48mo	-10.2%	$271.8M	-2.1	80	93	27.1%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $207.3M Cash: $51.9M FCF: $-5.8M ROE: -66.9% • D/E: 93% Profit Margin: -29.4% Quality FCF insufficient_data Full assessment →
OPRX OptimizeRx Corporation	6/12	0	CF+	-9.5%	$93.5M	12.1	70	18	23.1%	Health Tech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $107.3M Cash: $20.2M FCF: $11.3M ROE: 5.6% • D/E: 18% Profit Margin: 6.4% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
STTK Shattuck Labs, Inc.	6/12	9	26mo	-	$472.8M	-4.7	-298	3	51.5%	Biotech
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $1.0M Cash: $90.4M FCF: $-22.4M ROE: -61.0% • D/E: 3% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (9) • Heterodimeric proteins and uses thereof • Fusion proteins for the treatment of cardiometabolic diseases • Antibodies that bind TNFRSF25 +2 more — view all Red Flags SBC_HIGH (860% of revenue) Full assessment →
MNOV MediciNova, Inc.	6/12	8	34mo	-	$65.0M	-9.2	8	0	14.2%	Biotech
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.6M Cash: $27.3M FCF: $-6.0M ROE: -26.2% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (8) • Methods of treating post-COVID condition(s) • Treatment of progressive neurodegenerative disease with ibudilast • Methods of reducing plasma level of macrophage migratory inhibitory factor in patients +2 more — view all Red Flags SBC_HIGH (373% of revenue) Full assessment →
HNST The Honest Company, Inc.	6/12	0	CF+	-19.7%	$415.0M	11.6	40	7	10.1%	Consumer Defensive
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $352.2M Cash: $90.4M FCF: $48.1M ROE: -10.9% • D/E: 7% Profit Margin: -5.4% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
ALTO Alto Ingredients, Inc.	6/12	0	CF+	-0.8%	$389.0M	1.8	5	36	10.5%	Basic Materials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $916.1M Cash: $20.3M FCF: $6.8M ROE: 12.6% • D/E: 36% Profit Margin: 3.2% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
SELF Global Self Storage, Inc.	6/12	0	CF+	+1.5%	$58.0M	6.0	61	34	8.2%	Real Estate
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $12.8M Cash: $7.4M FCF: $3.5M ROE: 4.2% • D/E: 34% Profit Margin: 15.4% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
NPWR NET Power Inc.	6/12	0	24mo	-	$161.7M	-66.8	-	1	52.2%	Industrial Tech
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $308.0M FCF: $-108.0M ROE: -114.5% • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
SUPX SuperX AI Technology Limited	6/12	0	25mo	+130.4%	$354.2M	1.4	10	9	42.9%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $3.6M Cash: $17.2M FCF: $4.9M ROE: -158.4% • D/E: 9% Profit Margin: N/A Quality FCF+ Low Debt FCF insufficient_data Red Flags SBC_HIGH (358% of revenue) Full assessment →
PNRG PrimeEnergy Resources Corporati	6/12	0	CF+	-16.4%	$283.6M	10.8	66	0	63.2%	Energy
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $179.3M Cash: $19.4M FCF: $30.5M ROE: 10.2% • D/E: 0% Profit Margin: 12.0% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
CRBU Caribou Biosciences, Inc.	5/12	6	14mo	+1.9%	$162.7M	-39.0	-	26	4.4%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $11.2M Cash: $117.6M FCF: $-63.5M ROE: -83.5% • D/E: 26% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (6) • Anti-ROR1 antibody and ROR1-targeting engineered cells • Method of capturing CRISPR endonuclease cleavage products • Anti-ROR1 antibody and ROR1-targeting engineered cells +2 more — view all Red Flags SBC_HIGH (285% of revenue) Full assessment →
FATE Fate Therapeutics, Inc.	5/12	18	20mo	-20.3%	$243.6M	-20.6	-	43	12.6%	Biotech
Score Breakdown Patents: 3/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $6.3M Cash: $174.8M FCF: $-50.1M ROE: -55.5% • D/E: 43% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (18) • Combining iPSC derived effector cell types for immunotherapy use • Vial rack • Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs +2 more — view all Red Flags SBC_HIGH (424% of revenue) Full assessment →
HYSR SunHydrogen Inc.	5/12	0	87mo	-	$137.5M	-2.7	100	-	1.2%	Solar Energy
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $32.9M FCF: $-3.8M ROE: -15.6% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags SBC_HIGH (82770% of revenue) Full assessment →
LTBR Lightbridge Corporation	5/12	0	164mo	-	$322.9M	-3.0	-	-	5.4%	Electrical Equipment
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $215.7M FCF: $-9.8M ROE: -15.4% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $323M mcap) Full assessment →
INVZ Innoviz Technologies Ltd.	5/12	22	16mo	-59.0%	$128.8M	-14.4	10	58	9.1%	Consumer Cyclical
Score Breakdown Patents: 3/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $44.8M Cash: $60.1M FCF: $-18.5M ROE: -97.2% • D/E: 58% Profit Margin: -181.5% Quality FCF insufficient_data Patents (22) • Systems and methods for photodiode-based detection • Efficient optical transmission in LIDAR systems • Distributing LIDAR system components +2 more — view all Red Flags SBC_HIGH (84% of revenue) Full assessment →
ABOS Acumen Pharmaceuticals, Inc.	5/12	0	15mo	-	$163.2M	-41.3	-	36	48.9%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $128.4M FCF: $-67.4M ROE: -93.2% • D/E: 36% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
LUNG Pulmonx Corporation	5/12	0	25mo	-8.7%	$54.1M	-15.5	76	123	12.5%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $88.5M Cash: $61.6M FCF: $-8.4M ROE: -86.2% • D/E: 123% Profit Margin: -60.1% Quality FCF insufficient_data Full assessment →
REKR Rekor Systems, Inc.	5/12	2	9mo	+11.6%	$97.2M	-9.1	57	85	3.2%	Enterprise Software
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $49.5M Cash: $12.2M FCF: $-8.9M ROE: -88.3% • D/E: 85% Profit Margin: -60.5% Quality FCF insufficient_data Patents (2) • Systems and methods for efficient information extraction in traffic monitoring • Systems and methods for traffic monitoring with improved privacy protections Full assessment →
MAPS WM Technology, Inc.	5/12	0	CF+	-2.4%	$65.8M	19.3	95	19	9.6%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $173.7M Cash: $57.0M FCF: $12.7M ROE: 1.9% • D/E: 19% Profit Margin: 0.9% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
DUOT Duos Technologies Group, Inc.	5/12	0	38mo	-45.0%	$413.1M	-16.9	33	5	27.9%	Application Software
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $24.8M Cash: $33.0M FCF: $-69.9M ROE: -20.1% • D/E: 5% Profit Margin: -45.4% Quality Low Debt FCF insufficient_data Full assessment →
TTGT TechTarget, Inc.	5/12	0	CF+	+2.1%	$260.3M	8.3	60	26	69.8%	IT Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $489.0M Cash: $47.7M FCF: $21.7M ROE: -70.3% • D/E: 26% Profit Margin: -113.7% Quality FCF+ Low Debt FCF insufficient_data Red Flags SBC_HIGH (114% of revenue) Full assessment →
NKTX Nkarta, Inc.	5/12	3	32mo	-	$204.6M	-28.0	-	26	15.5%	Biotech
Score Breakdown Patents: 1/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $230.4M FCF: $-57.4M ROE: -30.1% • D/E: 26% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (3) • Immune cells comprising truncated NKG2D chimeric receptors • Genetically modified natural killer cells for CD70-directed cancer immunotherapy • CD19-directed chimeric antigen receptors and uses thereof in immunotherapy Red Flags HYPE_PRICING ($0.0M rev, $205M mcap) Full assessment →
CGEN Compugen Ltd.	5/12	0	CF+	-4.7%	$190.1M	-	88	3	2.3%	Biotech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $72.7M Cash: $134.9M FCF: N/A ROE: 45.7% • D/E: 3% Profit Margin: 48.0% Quality Low Debt High ROE Wide Moat FCF insufficient_data Full assessment →
BLNK Blink Charging Co.	5/12	1	27mo	+0.3%	$93.4M	11.1	28	14	1.2%	Industrials
Score Breakdown Patents: 1/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $103.6M Cash: $38.0M FCF: $10.4M ROE: -94.4% • D/E: 14% Profit Margin: -71.4% Quality FCF+ Low Debt FCF insufficient_data Patents (1) • Self-aligning holster for J1772 plug used in electric vehicle supply equipment Red Flags SBC_HIGH (55% of revenue) Full assessment →
INFU InfuSystems Holdings, Inc.	5/12	0	CF+	-3.0%	$190.1M	9.2	57	41	8.2%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $142.4M Cash: $2.1M FCF: $17.4M ROE: 13.9% • D/E: 41% Profit Margin: 5.6% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
EOLS Evolus, Inc. Common Stock	5/12	0	16mo	+6.7%	$436.6M	-5.3	66	-	24.0%	Pharma
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $301.8M Cash: $49.8M FCF: $-23.2M ROE: N/A • D/E: N/A Profit Margin: -14.4% Quality FCF insufficient_data Full assessment →
LRMR Larimar Therapeutics, Inc.	5/12	7	18mo	-	$378.1M	-18.9	-	2	42.3%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $200.4M FCF: $-71.3M ROE: -109.8% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (7) • Methods for treating myelin associated diseases and mitochondria associated diseases • Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof • Methods for quantifying frataxin activity +2 more — view all Red Flags HYPE_PRICING ($0.0M rev, $378M mcap) Full assessment →
RCEL Avita Medical, Inc.	5/12	4	6mo	+4.0%	$123.4M	-14.8	81	-	1.6%	Medical Devices
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $72.3M Cash: $14.3M FCF: $-18.3M ROE: N/A • D/E: N/A Profit Margin: -62.7% Quality FCF insufficient_data Patents (4) • Devices, methods, and kits for preparing a cell suspension • Automated method • System for automated preparation of a regenerative epidermal suspension and related methods of use +1 more — view all Full assessment →
GALT Galectin Therapeutics Inc.	5/12	1	8mo	-	$186.0M	-10.0	-	-	28.3%	Biotech
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $14.1M FCF: $-18.7M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (1) • Compounds for the prevention and treatment of medical disorders and uses thereof Full assessment →
HUMA Humacyte, Inc.	5/12	4	6mo	-4.3%	$249.3M	-26.0	-	572	29.3%	Biotech
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $2.0M Cash: $48.5M FCF: $-64.8M ROE: -409.5% • D/E: 572% Profit Margin: N/A Quality FCF insufficient_data Patents (4) • Fluid systems, apparatuses, devices and methods of management thereof for cultivating tissue • Tubular prostheses • Drawer system for cultivating tissue +1 more — view all Full assessment →
RPAY Repay Holdings Corporation	5/12	0	CF+	+4.5%	$298.6M	15.3	75	84	44.0%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $312.7M Cash: $43.8M FCF: $45.7M ROE: -43.9% • D/E: 84% Profit Margin: -82.7% Quality FCF+ FCF insufficient_data Red Flags SBC_HIGH (116% of revenue) Full assessment →
CRBP Corbus Pharmaceuticals Holdings	5/12	0	22mo	-	$153.0M	-28.3	-	1	22.7%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $138.2M FCF: $-43.3M ROE: -66.7% • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
TNYA Tenaya Therapeutics, Inc.	5/12	10	15mo	-	$158.5M	-26.4	100	10	0.4%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.2M Cash: $80.9M FCF: $-41.9M ROE: -73.6% • D/E: 10% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (10) • Gene therapy vectors for treating heart disease • Cardiac cell reprogramming with myocardin and ASCL1 • Optimized expression cassettes for gene therapy +2 more — view all Red Flags SBC_HIGH (8275% of revenue) Full assessment →
OKYO OKYO Pharma Limited	5/12	0	16mo	-	$83.4M	-3.6	-	-	60.8%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $4.2M FCF: $-3.0M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Full assessment →
BMEA Biomea Fusion, Inc.	5/12	9	10mo	-	$85.3M	-38.5	-	7	6.7%	Biotech
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.0M Cash: $44.7M FCF: $-32.9M ROE: -189.4% • D/E: 7% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (9) • Inhibitors of menin-mll interaction • Inhibitors of menin-MLL interaction • Pyrazine compounds as inhibitors of FLT3 +2 more — view all Full assessment →
TLSA Tiziana Life Sciences Ltd	5/12	1	4mo	-	$147.6M	-3.7	-	877	49.7%	Biotech
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $4.0M FCF: $-5.5M ROE: -924.3% • D/E: 877% Profit Margin: N/A Quality FCF insufficient_data Patents (1) • Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia Full assessment →
DAVA Endava plc	5/12	1	CF+	-8.4%	$140.0M	22.1	22	138	8.0%	Enterprise Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $727.6M Cash: $48.4M FCF: $30.9M ROE: -99.8% • D/E: 138% Profit Margin: -56.1% Quality FCF+ FCF insufficient_data Patents (1) • Interface for controlling at least one function of a unit of a motor vehicle Red Flags SBC_HIGH (61% of revenue) Full assessment →
HOVR New Horizon Aircraft Ltd.	5/12	0	16mo	-	$137.1M	-5.1	-	0	42.0%	Defense & Aerospace
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $19.7M FCF: $-7.0M ROE: -313.0% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
SES SES AI Corporation	5/12	0	38mo	+15.8%	$409.9M	-5.9	36	4	12.5%	Consumer Cyclical
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 2/3 • Mgmt: 1/3 Financials Revenue: $21.9M Cash: $177.7M FCF: $-24.4M ROE: -30.7% • D/E: 4% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (79% of revenue) Full assessment →
IPSC Century Therapeutics, Inc.	4/12	3	17mo	-	$413.0M	-13.0	-	18	45.7%	Biotech
Score Breakdown Patents: 1/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $134.8M FCF: $-53.6M ROE: -42.7% • D/E: 18% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (3) • Artificial cell death polypeptide for chimeric antigen receptor and uses thereof • Artificial cell death polypeptide for chimeric antigen receptor and uses thereof • Chimeric antigen receptor system with adaptable receptor specificity Red Flags HYPE_PRICING ($0.0M rev, $413M mcap) Full assessment →
VANI Vivani Medical, Inc.	4/12	0	9mo	-	$99.2M	-16.6	-	96	56.8%	Biotech
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $19.7M FCF: $-16.4M ROE: -176.4% • D/E: 96% Profit Margin: N/A Quality FCF insufficient_data Full assessment →
NNOX NANO-X IMAGING LTD	4/12	0	18mo	+24.0%	$116.2M	-21.8	-98	6	0.3%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 2/3 • Mgmt: 1/3 Financials Revenue: $13.0M Cash: $59.6M FCF: $-25.3M ROE: -45.6% • D/E: 6% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (263% of revenue) Full assessment →
DCGO DocGo Inc.	4/12	0	CF+	-21.3%	$51.7M	85.0	30	26	2.7%	Healthcare
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $301.7M Cash: $35.7M FCF: $44.0M ROE: -97.8% • D/E: 26% Profit Margin: -62.2% Quality FCF+ Low Debt FCF insufficient_data Red Flags SBC_HIGH (69% of revenue) Full assessment →
VUZI Vuzix Corporation	4/12	33	12mo	-12.0%	$275.3M	-4.6	-10	3	14.8%	Technology
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $6.1M Cash: $20.2M FCF: $-12.7M ROE: -91.9% • D/E: 3% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (33) • Wearable mobile electronic system • Color correction for virtual images of near-eye displays • Smart glasses +2 more — view all Red Flags SBC_HIGH (162% of revenue) Full assessment →
PRQR ProQR Therapeutics N.V.	4/12	0	20mo	-57.1%	$199.1M	-11.3	100	42	38.9%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $13.6M Cash: $81.1M FCF: $-22.5M ROE: -78.1% • D/E: 42% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
SGMO Sangamo Therapeutics, Inc.	4/12	24	4mo	-77.6%	$70.4M	-69.0	-228	-	10.7%	Biotech
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $34.6M Cash: $27.6M FCF: $-48.6M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (24) • Regulation of gene expression using engineered nucleases • Separation and quantification of empty and full viral capsid particles • Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene +2 more — view all Red Flags SBC_HIGH (95% of revenue) Full assessment →
BCYC Bicycle Therapeutics plc	4/12	0	29mo	-91.1%	$279.2M	-39.3	-244	3	0.0%	Biotech
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $63.5M Cash: $559.5M FCF: $-109.7M ROE: -33.8% • D/E: 3% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
DMAC DiaMedica Therapeutics Inc.	4/12	2	20mo	-	$315.2M	-5.7	-	0	46.6%	Biotech
Score Breakdown Patents: 1/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $51.3M FCF: $-18.0M ROE: -86.5% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (2) • Dosage forms of tissue kallikrein 1 • Dosage forms of tissue kallikrein 1 Red Flags HYPE_PRICING ($0.0M rev, $315M mcap) Full assessment →
GCTS GCT Semiconductor Holding, Inc.	4/12	0	3mo	+287.1%	$289.3M	-5.8	-22	-	26.7%	Semiconductors
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $4.3M Cash: $7.2M FCF: $-16.7M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags SBC_HIGH (376% of revenue) Full assessment →
IRD Opus Genetics, Inc.	4/12	5	18mo	-50.6%	$336.0M	-11.7	-179	-	23.2%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $12.0M Cash: $60.0M FCF: $-39.3M ROE: -7594.6% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (5) • Salts and esters of APX3330 and therapeutic uses thereof • Methods and compositions for treatment of mydriasis • Aqueous ophthalmic solutions of phentolamine and medical uses thereof +2 more — view all Red Flags SBC_HIGH (567% of revenue) Full assessment →
STXS Stereotaxis, Inc.	3/12	0	11mo	-15.8%	$183.7M	-4.8	54	27	29.3%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $31.2M Cash: $14.6M FCF: $-8.8M ROE: -156.1% • D/E: 27% Profit Margin: -69.5% Quality Low Debt FCF insufficient_data Full assessment →
ZNTL Zentalis Pharmaceuticals, Inc.	3/12	0	20mo	-	$263.4M	-30.9	-	21	31.2%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $211.8M FCF: $-81.4M ROE: -51.9% • D/E: 21% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $263M mcap) Full assessment →
MDAI Spectral AI, Inc.	3/12	0	12mo	-40.5%	$57.9M	-1.2	46	-	13.2%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $16.9M Cash: $11.7M FCF: $-0.7M ROE: N/A • D/E: N/A Profit Margin: -82.0% Quality FCF insufficient_data Full assessment →
RGNX REGENXBIO Inc.	3/12	6	8mo	-92.8%	$403.2M	-34.5	-197	1178	16.8%	Biotech
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $87.8M Cash: $150.5M FCF: $-139.0M ROE: -196.4% • D/E: 1178% Profit Margin: N/A Quality FCF insufficient_data Patents (6) • Anion exchange chromatography for recombinant AAV production • Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) • Treatment of mucopolysaccharidosis IVA +2 more — view all Red Flags SBC_HIGH (64% of revenue) Full assessment →
VERI Veritone, Inc.	3/12	6	4mo	-9.8%	$132.9M	-14.6	68	96	11.0%	Enterprise Software
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $90.0M Cash: $15.1M FCF: $-19.4M ROE: -349.4% • D/E: 96% Profit Margin: -123.8% Quality FCF insufficient_data Patents (6) • Controlling operation of an electrical grid using reinforcement learning and multi-particle modeling • Cognitive multi-factor authentication • Neural network orchestration +2 more — view all Red Flags SBC_HIGH (71% of revenue) Full assessment →
CRDF Cardiff Oncology, Inc.	3/12	3	15mo	-62.4%	$82.7M	-24.2	-	2	2.4%	Biotech
Score Breakdown Patents: 1/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $0.5M Cash: $46.1M FCF: $-20.0M ROE: -84.8% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (3) • PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer • PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer • Cancer treatment using FGFR inhibitors and PLK1 inhibitors Red Flags SBC_HIGH (1404% of revenue) Full assessment →
PRLD Prelude Therapeutics Incorporat	3/12	0	22mo	-	$344.1M	-5.2	100	29	57.5%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $16.7M Cash: $81.6M FCF: $-17.9M ROE: -95.2% • D/E: 29% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (204% of revenue) Full assessment →
BWEN Broadwind, Inc.	3/12	0	2mo	-7.5%	$117.7M	-6.9	11	42	14.0%	Industrial Tech
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $155.3M Cash: $0.9M FCF: $-8.1M ROE: 8.2% • D/E: 42% Profit Margin: 3.3% Quality Low Debt FCF insufficient_data Full assessment →
NINE Nine Energy Service, Inc.	3/12	0	9mo	-13.6%	$156.9M	-2.6	15	94	42.9%	Energy Services
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $541.4M Cash: $11.2M FCF: $-4.1M ROE: 201.6% • D/E: 94% Profit Margin: 11.5% Quality High ROE FCF insufficient_data Full assessment →
OPTT Ocean Power Technologies, Inc.	2/12	1	4mo	-37.8%	$66.7M	-23.7	-56	43	4.1%	Industrial Tech
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $3.4M Cash: $7.1M FCF: $-15.8M ROE: -147.0% • D/E: 43% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (1) • Floating charging station for an electric boat Red Flags SBC_HIGH (351% of revenue) Full assessment →
RCKT Rocket Pharmaceuticals, Inc.	2/12	0	10mo	-	$365.8M	-27.0	-	10	19.7%	Biotech
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $144.4M FCF: $-98.9M ROE: -64.4% • D/E: 10% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $366M mcap) Full assessment →
CNTB Connect Biopharma Holdings Limi	2/12	0	10mo	-	$125.9M	-26.9	100	2	70.0%	Biotech
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.2M Cash: $46.0M FCF: $-33.9M ROE: -102.9% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (3156% of revenue) Full assessment →
CBUS Cibus, Inc.	2/12	2	2mo	-12.8%	$110.1M	-47.0	100	1228	32.1%	Biotech
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $3.6M Cash: $9.9M FCF: $-51.8M ROE: -221.0% • D/E: 1228% Profit Margin: N/A Quality FCF insufficient_data Patents (2) • Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair • Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair Red Flags SBC_HIGH (2102% of revenue) Full assessment →
REA Rare Earths Americas, Inc.	2/12	0	0mo	-	$339.8M	-0.7	-	-	67.9%	Basic Materials
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $0.0M FCF: $-2.3M ROE: -70.4% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $340M mcap) Full assessment →
SWMR Swarmer, Inc	2/12	0	34mo	-81.6%	$453.7M	-	20	1	55.2%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 0/3 Financials Revenue: $0.2M Cash: $23.5M FCF: N/A ROE: N/A • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (1857% of revenue) HYPE_PRICING ($0.2M rev, $454M mcap) Full assessment →
NUCL Eagle Nuclear Energy Corp.	2/12	0	3mo	-	$332.8M	-1.3	-	5	-24.5%	Nuclear Energy
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $1.3M FCF: $-4.3M ROE: -987.2% • D/E: 5% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $333M mcap) Full assessment →

38 stocks auto-rejected (red flags)

MCRB reverse_split

EVTL reverse_split

STEM reverse_split

ARQQ reverse_split

SPCE reverse_split

LIDR reverse_split

WATT reverse_split

ACET reverse_split

KORE reverse_split

KULR reverse_split

SENS reverse_split

NRXP reverse_split

AGEN reverse_split

DTIL reverse_split

KALA reverse_split

KPTI reverse_split

PYPD reverse_split

LYEL reverse_split

ASRT reverse_split

MNPR reverse_split

SABS reverse_split

BNED reverse_split

XFOR reverse_split

COOK reverse_split

DPRO reverse_split

YSG reverse_split

GDEV reverse_split

VIVO reverse_split

FBIO reverse_split

BNAI reverse_split

SRZN reverse_split

IBIO reverse_split

TNXP reverse_split

DVLT reverse_split

NGNE reverse_split

ASMB reverse_split

GRRR reverse_split

SIDU reverse_split

Disclaimer: Micro cap stocks are inherently risky. This screener identifies innovation signals — it is not a buy recommendation. Always do your own due diligence. See our 7-step risk assessment methodology and full disclaimer.